Sarepta's Troubling Times

This chapter examines the sharp decline in Sarepta's stock following the FDA's request to halt shipments of its gene therapy, amidst concerns over fatalities linked to the treatment. It also delves into the broader financial market landscape, analyzing recent earnings reports, tax incentives, and the role of AI investments in sustaining market momentum.